GH insider filing: 116 shares to be sold after restricted stock lapse
Rhea-AI Filing Summary
Form 144 notice for Guardant Health, Inc. (GH) reporting a proposed sale of 116 common shares through Charles Schwab & Co., Inc. on 08/19/2025 with an aggregate market value of $6,846.00. The shares were acquired on 08/15/2025 via a restricted stock lapse from Guardant Health and the payment/nature is listed as equity compensation. The filer or seller identified in prior transactions is Musa Tariq, who sold shares on 05/19/2025 (116 shares, $4,645.00), 06/18/2025 (3,213 shares, $158,947.00), and 07/17/2025 (116 shares, $5,591.00). The form includes the standard representation that the seller has no undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider notice showing small incremental sales and a planned sale following restricted stock vesting; limited immediate market impact.
The filing documents a proposed sale of 116 shares following a restricted stock lapse and lists three recent sales by the same person totaling 3,561 shares sold across May–July 2025. The planned sale size relative to the reported outstanding share count (124,705,857) is immaterial based on the data in the form. This is a standard compliance disclosure under Rule 144; it confirms transferability and planned market sale but provides no operating or financial performance information about the issuer.
TL;DR: Form 144 reflects compliance with resale rules after equity compensation vesting; no governance red flags disclosed.
The notice records that the securities were acquired via equity compensation and that the seller affirms absence of undisclosed material information. The form includes broker details and recent sale history, which supports transparency around insider dispositions. There is no information in this filing indicating unusual timing, related-party transfers, or triggering governance events.
FAQ
What does Guardant Health (GH) Form 144 filed here disclose?
Who is the seller named in the filing for GH?
How were the 116 shares being sold on 08/19/2025 acquired?
Does the Form 144 indicate any undisclosed material information about Guardant Health?
What broker is handling the proposed sale in the GH Form 144?